Comparative Pharmacology
Head-to-head clinical analysis: CHOLOVUE versus CONRAY 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOVUE versus CONRAY 400.
CHOLOVUE vs CONRAY 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Complexes with anions in the gastrointestinal tract to increase fecal elimination of iodipamide, reducing systemic absorption and enhancing gallbladder visualization.
Iodinated radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing radiographic contrast in imaging procedures.
100 mg/kg intravenously over 30 minutes every 3-4 weeks.
0.5-1.0 mL/kg (up to 150 mL total) intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in patients with normal renal function; prolonged to 15–20 hours in moderate renal impairment (CrCl 30–50 mL/min) and >24 hours in severe renal failure.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged significantly.
Primarily renal; approximately 70% excreted unchanged in urine within 24 hours, with the remainder eliminated as glucuronide conjugates via biliary/fecal route (20%) and minor metabolic pathways (10%).
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent